Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

X

after three months of therapy or sooner if significant neurotoxicity

develops (Grade 3 or greater). Nephrotoxicities and ototoxicities

were rare and mild.

Based on this promising data, in November 2007 we initiated a

randomized, Phase 2 study comparing picoplatin to oxaliplatin, both

in combination with 5-fluorouracil and leucovorin. We announced

today that we completed the Phase 2 enrollment. This randomized,

controlled 100-patient trial is designed to compare the safety and

efficacy of picoplatin given once every four weeks in combination

with full-dose 5-fluorouracil and leucovorin dosing in the FOLPI

regimen to oxaliplatin in combination with 5-fluorouracil and

leucovorin in the modified FOLFOX-6 regimen.

We currently are on track to generate data from this trial

throughout 2008 and beyond, and will be presenting early Phase 2 and

updated Phase 1 data at ASCO in June this year.

* Prostate Cancer: At the February 2008 ASCO Genitourinary Cancers

Symposium, we reported encouraging safety and efficacy data from our

Phase 1 dose-escalation study of picoplatin in combination with

docetaxel and prednisone in patients with hormone refractory

prostate cancer (HRPC). Picoplatin was safely administered in

combination with full-dose docetaxel and prednisone, the current

standard of care for first-line HRPC patients. The follow-up Phase 2

study completed enrollment late 2007 and we plan to present data

from this study at ASCO this June and at other scientific meetings.

* Oral Picoplatin: In April this year, results were presented from the

ongoing Phase 1 clinical trial of oral picoplatin in patients with

advanced solid tumor malignancies at the Annual Mee
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at the ... recently there has been a promotion of the idea that ... seed, or low dose rate, brachytherapy for prostate cancer. The ... a shorter half life, and gives a higher biologically effective ... has a higher average energy than the other commonly used ...
(Date:5/24/2013)... 24, 2013 Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... , Ph.D., the Company,s Vice President, Biology and ... & Corporate Communications, will present an overview of Senomyx,s ... a.m. Eastern Time (7:25 a.m. Pacific Time) during the ...
(Date:5/24/2013)... Madison, WI (PRWEB) May 24, 2013 ... to the discovery and development of calcium-binding proteins ... publication of safety assessment study of apoaequorin ... an international journal published for the British Industrial ... the study was to investigate potential adverse effects, ...
(Date:5/23/2013)... Can economic incentives such as gift ... of the public to increase their donations of blood? ... Carey Business School Assistant Professor Mario Macis says ... large body of recent research that supports their argument, ... issue of Science that the World Health Organization and ...
Breaking Biology Technology:Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... Feb. 9 Celsis In Vitro Technologies (Celsis,IVT), ... life science,products and laboratory services company, and Wisconsin-based ... of ADME-Tox testing in primary,hepatocytes. Celsis IVT ... use with Promega,s bioluminescent ADME-Tox assays, including,the P450-Glo(TM) ...
... of Pharmaceuticals in a New U.S. Political AdministrationPHILADELPHIA, ... start of the first annual conference on Managed ... at the Loews Philadelphia Hotel. The conference ... needed to prepare for future changes in health ...
... Measuring Prevalence of Sleep Apnea Among Insomnia PatientsALBUQUERQUE, N.M., ... (SHHI) was awarded a grant to study one of ... connects insomnia to psychological factors -- stress, racing thoughts, ... pills or talk therapy. Pitted against the CW ...
Cached Biology Technology:Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 3Controversial Study to Test Link Between Insomnia and Sleep Apnea 2
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than 165 ... intellectual property at PNNL,s annual Intellectual Property Commercialization ... Department of Energy national laboratory named materials scientist ... work developing battery materials that can store large ... grid, and reduce the time it takes to ...
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Biochemistry: Unspooling DNA from nucleosomal disks 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... inventions are birthed at a bar, their futures scribbled ... technological change in X-rays in more than a century, ... It was 2000. Otto Zhou was the principal investigator ... Naval Research to find applications for carbon nanotubes. Zhou ...
... atmospheric mercury emissions should quickly reduce mercury levels in ... week in the Proceedings of the National Academy of ... loading at rates relevant to atmospheric deposition resulted in ... fish in only three years. This is ...
... and ... terminal solutions, WALL, N.J., Sept. 18 ... in finger-based biometric,identification and wireless public safety solutions, ... technology to the hospitality and,retail industries, announced today ...
Cached Biology News:UNC nanotech spin-off forms new venture with Siemens 2UNC nanotech spin-off forms new venture with Siemens 3New study shows fish respond quickly to changes in mercury deposition 2New study shows fish respond quickly to changes in mercury deposition 3Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution 2Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution 3
...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: